Omalizumab: all 165 studies that test it

Page 2 of 2. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.

• Preclinical Studies of Omalizumab in Chronic Rhinosinusitis With Nasal PolyposisCompletedNCT04583501Early Phase 1
• Xolair Interventional Study in ASD Patients With Comorbid AtopyWithdrawnNCT04535817Phase 1
• The Efficacy of Preseasonal Omalizumab TreatmentCompletedNCT04489121Not applicable
• Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous PemphigoidWithdrawnNCT04128176Phase 3
• Omalizumab to Accelerate a Symptom-driven Multi-food OITActive, not recruitingNCT04045301Phase 2
• Behandling af Boern Med Foedevareallergi Med Omalizumab (Xolair)CompletedNCT04037176Phase 4
• Protection From Food Induced Anaphylaxis by Reducing the Serum Level of Specific IgE (Protana).TerminatedNCT03964051Phase 4
• Treatment With the Anti-IgE Monoclonal Antibody Omalizumab in Women With Asthma Undergoing Fertility Treatment. - A Proof of Concept Study.CompletedNCT03727971Phase 2
• Omalizumab Treatment in Venom Immunotherapy With Systemic ReactionsStatus unknownNCT02968394Not applicable
• Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic UrticariaCompletedNCT02814630Not applicable
• Preventing Asthma in High Risk KidsActive, not recruitingNCT02570984Phase 2
• Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral ImmunotherapyStatus unknownNCT02402231Phase 2
• Role of Anti-IgE in Severe Childhood EczemaCompletedNCT02300701Phase 4
• Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity ReactionCompletedNCT02266355Phase 1
• Efficacy and Safety of Omalizumab in Patients With Severe Acute UrticariaStatus unknownNCT02191072Not applicable
• Efficacy and Safety of Omalizumab in Chronic Idiopathic UrticariaStatus unknownNCT02166151Phase 3
• Study of Omalizumab as Adjuvant Therapy in Chemotherapy DesensitizationCompletedNCT02118987Phase 1
• Efficacy Study of Omalizumab in Cholinergic UrticariaCompletedNCT02012387Phase 2
• Safety and Efficacy Study of Omalizumab to Treat Allergic AsthmaCompletedNCT01976208Phase 2/3
• Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)WithdrawnNCT01893658Phase 2
• Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria PatientsCompletedNCT01803763Phase 2/3
• Omalizumab for LupusCompletedNCT01716312Phase 1
• Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic UrticariaCompletedNCT01713725Phase 2
• Single Center Study Using Omalizumab in Subjects With Atopic DermatitisCompletedNCT01678092Phase 1
• mRNA Expression as a Biomarker of Omalizumab ResponseStatus unknownNCT01584687Phase 4
• Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single CenterCompletedNCT01510626Phase 1
• Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and AsthmaCompletedNCT01393340Phase 2
• Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese ChildrenCompletedNCT01328886Phase 3
• Omalizumab in Interstitial Cystitis/Bladder Pain SyndromeCompletedNCT01294878Phase 3
• Atopic Dermatitis Biomarker Identification Trial in Omalizumab UsageCompletedNCT01179529Phase 2
• Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years)CompletedNCT01155700Phase 3
• Omalizumab in Non-atopic AsthmaStatus unknownNCT01113437Phase 2/3
• Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease ModelCompletedNCT01040598Phase 1
• Xolair Treatment for Milk Allergic ChildrenCompletedNCT00968110Early Phase 1
• Exploratory Study of Xolair in Chronic Obstructive Pulmonary Disease in Patients With Elevated IgE LevelsWithdrawnNCT00851370Phase 2
• Study to Determine the Effect of an Anti-IgE Agent on Inflammatory Cells in the Skin of Atopic Dermatitis PatientsCompletedNCT00822783Phase 4
• Non-invasive Measures of Effects of Xolair in AsthmaTerminatedNCT00784485Phase 4
• Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled CorticosteroidsCompletedNCT00691873Phase 4
• The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood BasophilsStatus unknownNCT00673218Phase 4
• The Effect of Xolair (Omalizumab) on Allergy Blood CellsCompletedNCT00657891Phase 4
• A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal TherapyCompletedNCT00639691Phase 4
• Effects of Anti-IgE Antibody Omalizumab on Patients With Chronic SinusitisWithdrawnNCT00603785Phase 4
• Safety and Tolerability of Omalizumab in Patients With Mild to Moderate AsthmaCompletedNCT00546143Phase 4
• Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma PatientsCompletedNCT00482508Phase 3
• Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic AsthmaCompletedNCT00482248Phase 3
• A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO)CompletedNCT00401596Phase 3
• Safety and Efficacy Study of Omalizumab Given Prior to ImmunotherapyCompletedNCT00329381Phase 4
• Effect of Ozone on Airway Inflammation in Allergic Asthmatics Treated With OmalizumabTerminatedNCT00287378Not applicable
• Effect of Omalizumab (Xolair) in Treatment of Patients With AERD and Allergy AsthmaStatus unknownNCT00286416Not applicable
• Omalizumab to Treat Hyper-IgE (Job's) SyndromeCompletedNCT00260702Phase 1
• A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced AsthmaWithdrawnNCT00242359Phase 4
• Study of Omalizumab in Moderate to Severe Bronchial AsthmaCompletedNCT00232050Phase 3
• Soluble CD23 Expression in Asthma Patients Treated With OMATerminatedNCT00226200Not applicable
• Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.CompletedNCT00219323Phase 3
• Effect of Xolair on Airway HyperresponsivenessStatus unknownNCT00208234Phase 4
• Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe AsthmaCompletedNCT00180011Phase 2/3
• Non-invasive Ways to Evaluate Lung Disease After Treatment With XolairCompletedNCT00139152Phase 4
• The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With Poorly Controlled AsthmaCompletedNCT00133042Phase 4
• Effect of Anti-IgE in Chronic UrticariaCompletedNCT00130234Phase 2
• A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic AsthmaCompletedNCT00109200Phase 3
• An Extension Study of Xolair in Moderate to Severe, Persistent Asthma Patients Who Completed Study Q2143gCompletedNCT00109187Phase 3
• A Safety and Efficacy Study of Xolair in Peanut AllergyTerminatedNCT00086606Phase 2
• Omalizumab to Treat Eosinophilic GastroenteritisCompletedNCT00084097Phase 2
• Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal AllergiesCompletedNCT00078195Phase 2
• Efficacy and Safety of Omalizumab in Patients With Severe Persistent AsthmaCompletedNCT00046748Phase 3

← Omalizumab overview